Chaohong He

发表

Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial

T. Chong, X. Qin, D. Ji, 2022, BMC Medicine.

The Modification and Optimization of Retroperitoneal Laparoscopic Radical Nephrectomy for the Treatment of Localized Renal Cell Carcinoma

P. Tian, Chaohong He, Yimu Zhang, 2020 .

Association of Myeloid-derived Suppressor Cells and Efficacy of Cytokine-induced Killer Cell Immunotherapy in Metastatic Renal Cell Carcinoma Patients

Yongping Song, Lingdi Zhao, Q. Gao, 2014, Journal of immunotherapy.

Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study

D. Ye, N. Xing, Quanren Wang, 2022, Journal for ImmunoTherapy of Cancer.

Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study

D. Ye, N. Xing, Hai-Liang Zhang, 2021, Clinical Cancer Research.

Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT).

Zhiquan Hu, F. Zhou, Peng-Yu Chen, 2022, European journal of cancer.

HMMR is a downstream target of FOXM1 in enhancing proliferation and partial epithelial-to-mesenchymal transition of bladder cancer cells.

Yan Ma, Jing Ma, Chaohong He, 2021, Experimental cell research.

A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer

Xiangliang Zhang, Degang Ding, S. Cui, 2020, Cancer biology & medicine.

Combining Protein and miRNA Quantification for Bladder Cancer Analysis.

Fuqing Zeng, Ruixue Duan, A. Hakeem, 2017, ACS applied materials & interfaces.

Systematic screening of protein-coding gene expression identified HMMR as a potential independent indicator of unfavorable survival in patients with papillary muscle-invasive bladder cancer.

Yan Ma, Jing Ma, Chaohong He, 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Camrelizumab plus famitinib for advanced renal cell carcinoma or unresectable urothelial carcinoma: Updated results from a phase II trial.

D. Ye, N. Xing, Hai-Liang Zhang, 2021 .

Camrelizumab plus famitinib malate in patients with advanced renal cell cancer and unresectable urothelial carcinoma: A multicenter, open-label, single-arm, phase II trial.

D. Ye, Hongqian Guo, Quanren Wang, 2020 .

PD-1 inhibitor toripalimab with gemcitabine as a neoadjuvant therapy for muscle-invasive bladder urothelial carcinoma

Yongkang Ma, Yang Tiejun, Tiejun Yang, 2022, Medicine.

Combining Protein and miRNA Quantification for Bladder Cancer Analysis.

Fuqing Zeng, Ruixue Duan, A. Hakeem, 2017, ACS applied materials & interfaces.

Pancreatic Metastasis from Prostate Cancer: A Case Report

Chaohong He, Yimu Zhang, Dong Yang, 2020 .